Author Archives | Simplyjo
Simplyjo - who has written 81 posts on FavStocks.
I have done by Post Graduation in Tourism from College of Vocational Studies apart from a full time MBA degree in Finance.I have worked with several reputed companies including IBM, MakeMyTrip and Habitat World.
I love to read, write and travel.
Currently, I am a SAHM ,earning a living off the stock market and making a killing with forex trades. I am sharing my knowledge so as to help others learn and expand their horizon.
OncoVista’s AdnaGen Test (OTC:OVIT)
OncoVista Innovative Therapies, Inc (OTC:OVIT) reported that two of their proprietary products, AdnaTest BreastCancer and AdnaTest ETM1/Stem Cell were being evaluated in Germany by the Department of Gynecology and Obstetrics and Internal Medicine at University Hospital Essen, University of Duisburg-Essen and University Hospital of Tuebingen and it was found that the research has been accepted [...]
Continue reading...Ziopharm Shows Positive Results (NASDAQ:ZIOP)
9 November 2009
Comments Off
Ziopharm Oncology, Inc. (NASDAQ:ZIOP) has announced today and presented their positive interim data from the multicenter randomized Phase 2 trial of Palifosfamide also known as Zymafos that will be used for the treating patients with unresectable or metastatic soft tissue sarcoma.
Continue reading...PPD Acquires Excel PharmaStudies (NASDAQ:PPDI)
9 November 2009
Comments Off
PPD or Pharmaceutical Product Development, Inc (NASDAQ:PPDI) today announced that they have completed their acquisition of Excel PharmaStudies Inc which is considered to be the market leader and one of the largest contract research organizations in China.
Continue reading...QuantRx’s Diagnostic Reader (OTC:QTXB)
9 November 2009
Comments Off
QuantRx Biomedical Corporation (OTC:QTXB) has announced that the Company will soon demonstrate its latest technology at the MEDICA 2009.
Continue reading...Ligand Pfizer Collaboration Extended (NASDAQ:LGND)
6 November 2009
Comments Off
Ligand Pharmaceuticals Inc (NASDAQ:LGND) has announced that they have extended their research collaboration with Pfizer for JAK3 by one year.
Continue reading...MabCure Signs Research Agreement (OTC:MBCI)
5 November 2009
MabCure N.V., a subsidiary of MabCure Inc (OTC:MBCI) today announced that they have signed a research agreement with AZ Sint Lucas Hospital in Belgium to conduct preclinical research on its monoclonal antibodies against different cancers. Currently, the company’s monoclonal antibodies for the diagnosis of ovarian cancer, prostrate cancer, and colorectal cancer are aimed at diagnosing [...]
Continue reading...Omnicare Finalized Settlement Agreement (NYSE:OCR)
4 November 2009
Comments Off
Omnicare, Inc. (NYSE:OCR) have announced today that they have gone ahead and finalized the previously disclosed agreement for a voluntary civil settlement with the US Attorney’s Office, District of Massachusetts, the Department of Justice and Health and Human Services, as well as various of the states in which the Company runs its business.
Continue reading...RXi’s Therapeutic Platform (NASDAQ:RXII)
4 November 2009
Comments Off
RXi Pharmaceuticals Corporation (NASDAQ:RXII) announced that their Vice President of Technology Development, Dmitry Samarsky will be presenting their new RNAi technology development at the Discovery on Target scientific conference in Boston on November 4, 2009.
Continue reading...Ariad’s AP24534 in Publication (NASDAQ:ARIA)
3 November 2009
Comments Off
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that Cancer Cell, one of the leading scientific journals, has published a comprehensive paper describing the design and preclinical characterization of an investigational kinase inhibitor (AP24534).
Continue reading...Enzo Biochem NASH Results (NYSE:ENZ)
3 November 2009
Comments Off
Enzo Biochem Inc. (NYSE:ENZ) announced today that they have favorable results of the Company’s clinical trial for the treatment of non-alcoholic steatohepatitis.
Continue reading...
11 November 2009
View Comments